Australia-based Nufarm Limited’s seed-technology arm has recently closed the acquisition of substantially all of Yield10 Bioscience’s assets, completing a transaction first outlined in mid-2024. The deal, finalized in January 2025, transfers Yield10’s entire camelina R&D portfolio—including omega-3, herbicide tolerance, and bio-energy traits—for a consideration of up to USD $5 million, as set out in the October 2024 asset-purchase agreement.
